Navigation Links
New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R)
Date:9/19/2008

he level of disability at the start of treatment and cognitive function 16 years later. More research is needed to determine how treatment might benefit long-term cognitive outcome," said Dr. Goodin.

"The data presented here underscore the need to help patients start therapy earlier and stay on treatment for the long-term," said, Ludger Heeck, Ph.D. Vice President and General Manager, Specialty Medicine Bayer HealthCare Pharmaceuticals Inc. "Bayer is committed to helping provide both the medication and the support services that people need to help treat their MS. We pioneered the concept of customized MS support services, and our best-in-class BETAPLUS(TM) program goes far beyond treatment to offer a wide range of beneficial services for people with MS. From having dedicated MS nurses who can provide practical help and advice, to offering product enhancements like our new thinnest needle and optional autoinjector that can help make injection administration more comfortable, we continue to lead the way in helping people with MS start on and stay on treatment."

About the Trials

The 16-Year Long-term Follow-up Study is a multicenter observational study that collected data from patients with relapsing-remitting MS (RRMS) who participated in the pivotal North American trials for Betaseron. Several statistical methods were used to assess patient data and examine the relationship between timing of drug exposure and long-term outcomes. Drug exposure was measured as the medication possession ratio (MPR) defined as the actual time the patient received therapy divided by the total time possible before a negative outcome was reached (or at data censor). A statistical method called recursive partitioning was then used to divide treatment groups into "high" or "low" exposure and to determine the relationship between length of drug exposure and long-term outcomes. The use of MPR reduces the bias introduced in long-term trials by the tendency of patients who ar
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium
2. Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
3. TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
4. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
5. First Ever Study on Alzheimers Disease Treatment in Hispanics Presented at Major Medical Meeting
6. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
7. Positive Mid-Term Results on CryoValve(R) SG Pulmonary Human Heart Valve Presented at Western Thoracic Meeting
8. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
9. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
10. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
11. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... collaboration, according to a new report from Kalorama ... 100 deals had occurred in proteomics in the ... and IPOs, to agreements between private proteomic companies ... biotech companies with novel proteomics innovator companies.  Kalorama ...
(Date:9/30/2014)... , 30. September 2014 ... http://photos.prnewswire.com/prnh/20130430/LA01948LOGO Acutus ... ein minimal-invasives 3D-Herzkammer-Bildgebungs- und Dipoldichte-Mappingsystem in ... die zu komplexen Herzrhythmusstörungen einschließlich Vorhofflimmern ... Abschluss einer zusätzlichen Finanzierung über 26,2 ...
(Date:9/30/2014)... and LONDON , Sept. 30, 2014 /PRNewswire/ ... Ltd. announces its major milestone: Alzheimer,s Team ... caters to patients, families and caregivers, was developed to ... evolving treatments for Alzheimer,s disease. It also provides inspirational ... Alzheimer,s ranks as the leading healthcare concern ...
Breaking Medicine Technology:Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3MediciGlobal's Alzheimer's Community Reaches 200,000 likes and more than half a million weekly visitors 2MediciGlobal's Alzheimer's Community Reaches 200,000 likes and more than half a million weekly visitors 3MediciGlobal's Alzheimer's Community Reaches 200,000 likes and more than half a million weekly visitors 4
... 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: ... cord blood collection, laboratory testing, hematopoietic stem cell processing, and ... results for the second quarter and first half of fiscal ... Second Quarter of Fiscal 2012 Highlights Revenue ...
... 28, 2011  Johnson & Johnson (NYSE: JNJ ) will ... Conference on Tuesday, Nov. 29 th at The New York ... present in a session scheduled at 8:00 a.m. (Eastern Time). ... interested parties by accessing the Johnson & Johnson website at ...
Cached Medicine Technology:China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012 2China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012 3China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012 4China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012 5China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012 6China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012 7China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012 8China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012 9China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012 10
(Date:9/30/2014)... Because heart cells cannot multiply and cardiac muscles ... to repair itself after a heart attack. Now ... new gold standard in cardiac tissue engineering. , ... Shevach of TAU,s Department of Biotechnology, Department of ... and Nanotechnology, have been developing sophisticated micro- and ...
(Date:9/30/2014)... Dublin, Ireland, September 30th, 2014 A new ... to TILDA (The Irish Longitudinal Study on Ageing) ... and Midwifery, Trinity College Dublin, Ireland, has highlighted ... challenges facing Ireland,s intellectual disability population. , The ... kind in Europe and the only one in ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 MyServer2Go.com ... Arvixe as the Best VPS Hosting this year for ... well as affordable price. , MyServer2Go.com is a ... of VPS hosting services. And this announcement will help ... , According to MyServer2Go.com, Arvixe ( http://www.arvixe.com ) is ...
(Date:9/30/2014)... September 30, 2014 The accurate ... improve breast cancer risk prediction and to tailor ... study published in Breast Cancer Research (BCR September ... and breast cancer risk: a case-control study of ... connection between breast density and breast cancer risk. ...
(Date:9/30/2014)... choice to die at home surrounded by loved ones ... happens and how to change the process so that ... focus of new research the Frances Payne Bolton School ... with a four-year, $2.06 million grant from the National ... "Mapping Complex Influences of Aggressiveness of End of Life ...
Breaking Medicine News(10 mins):Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 2Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 3Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 4Health News:Arvixe Is Named Best VPS Hosting by MyServer2Go.com 2Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 2Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 3Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 4Health News:CWRU researchers receives $2.06 million to study how patients make end-of-life decisions 2
... As the general election,campaign begins in earnest today, ... is looking to the two presidential,candidates for a ... Now that the Democratic and Republican conventions are ... the significant obstacles faced,by small businesses as they ...
... disease resistance to anti-hormonal therapy , , FRIDAY, Sept. ... help "re-sensitize" certain breast cancer tumors to anti-hormonal ... , Women with estrogen-receptor or progesterone-receptor positive (ER ... anti-hormonal medicines, such as aromatase inhibitors, to keep ...
... hormone-receptor positive, metastatic breast cancer may take medications for ... when the tumor becomes resistant to anti-hormonal drugs, treatment ... presented today at the 2008 ASCO Breast Cancer Symposiummay ... treatment approach can "re-sensitize" the tumor, allowing anti-hormonal drugs ...
... to Feature VelaShape. , ... New York, New York ... Centers __title__ American Laser], the largest provider of laser hair removal ... the STYLE360 show during New York Fashion Week. STYLE360, from ...
... Free drug samples provided to physicians by pharmaceutical companies ... long run, according to a study done by researchers ... , The retrospective study looked at the prescribing habits ... medicine practice in the months immediately before and after ...
... September 3, 2008In a case-control study, the presence of ... with autism and GI disturbances than in children with ... onset were unrelated to MMR vaccine timing. Study ... of Science on September 4 ( http://dx.plos.org/10.1371/journal.pone.0003140 ). ...
Cached Medicine News:Health News:Conventions Conclude, Fall Campaign Begins: NFIB Looks for More Focus on Small Business Healthcare Concerns 2Health News:Conventions Conclude, Fall Campaign Begins: NFIB Looks for More Focus on Small Business Healthcare Concerns 3Health News:Drug Re-Sensitizes Breast Tumors to Treatment 2Health News:1 step back ... 2 steps forward 2Health News:American Laser Centers Sponsors STYLE360 to Share the Skinny on Body Shaping 2Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 2Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 3
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
... technology allows the grasper ... a shorter length and ... the stone. The Unidex ... one-handed operation. Supplied sterile ...
Bugbee Fulgurating...
Fulgurating Electrode, 2 F...
Medicine Products: